Genmab Logo

Genmab

Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.

GMAB | CO

Overview

Corporate Details

ISIN(s):
DK0010272202 (+2 more)
LEI:
529900MTJPDPE4MHJ122
Country:
Denmark
Address:
Carl Jacobsens Vej 30, 2500 Valby
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genmab is an international biotechnology company focused on creating and developing differentiated antibody therapeutics for the treatment of cancer and other serious diseases. The company leverages its proprietary antibody science and pioneering technology platforms to innovate next-generation treatments. Genmab's core activities involve the discovery, development, and commercialization of antibody-based products, often in collaboration with strategic partners. Its purpose is to improve the lives of patients by harnessing the power of antibodies to transform medical care.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-19 18:55
Regulatory Filings
English 206.6 KB
2025-11-19 18:55
Director's Dealing
English 7.0 KB
2025-11-18 20:58
Share Issue/Capital Change
English 176.0 KB
2025-11-18 20:58
Share Issue/Capital Change
English 7.8 KB
2025-11-18 17:30
Regulatory Filings
English 244.6 KB
2025-11-18 17:30
Regulatory Filings
English 27.2 KB
2025-10-14 12:23
Earnings Release
English 216.5 KB
2025-10-14 12:23
Earnings Release
English 7.7 KB
2025-09-29 07:08
M&A Activity
English 25.9 KB
2025-09-29 07:08
M&A Activity
English 234.3 KB
2025-09-23 15:18
Major Shareholding Notification
English 175.3 KB
2025-09-23 15:18
Major Shareholding Notification
English 7.2 KB
2025-09-23 15:18
Major Shareholding Notification
English 2.9 MB
2025-09-09 20:57
Director's Dealing
English 7.1 KB
2025-09-09 20:57
Director's Dealing
English 202.5 KB

Automate Your Workflow. Get a real-time feed of all Genmab filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genmab

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genmab via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

UNION KOREA PHARM CO.,Ltd Logo
Develops and manufactures prescription drugs like antibiotics and analgesics for global markets.
South Korea
080720
uniQure N.V. Logo
Developing AAV-based gene therapies for rare liver and central nervous system disorders.
United States of America
QURE
UNITED THERAPEUTICS Corp Logo
Develops therapies for chronic diseases and manufactures organs for transplantation.
United States of America
UTHR
Universe Pharmaceuticals INC Logo
Manufactures, markets, and distributes TCM derivative products and biomedical drugs.
United States of America
UPC
Univo Pharmaceuticals Ltd. Logo
Vertically integrated biopharma firm developing medical cannabis treatments with a focus on CNS.
Israel
UNVO-M
Upstream Bio, Inc. Logo
Developing a monoclonal antibody for severe inflammatory and respiratory diseases.
United States of America
UPB
UroGen Pharma Ltd. Logo
Develops non-surgical therapies for urological cancers using proprietary hydrogel technology.
United States of America
URGN
Valneva SE Logo
Develops and commercializes vaccines for infectious diseases like chikungunya, Lyme, and Zika.
France
VLA
Vanda Pharmaceuticals Inc. Logo
Develops and commercializes innovative therapies for central nervous system disorders.
United States of America
VNDA
Vaxcell-Bio Therapeutics Logo
Develops CAR-T and CAR-NK immunotherapies for solid tumors and canine lymphoma.
South Korea
323990

Talk to a Data Expert

Have a question? We'll get back to you promptly.